SEC Form 4 · accession 0000899243-16-033398
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
James N Wilson
Director
Period of report
Nov 9, 2016
Accepted (ET)
Nov 14, 2016 · 7:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 9, 2016 | M | 111,349 | $1.51 | A | 1,012,416 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common StockF1 | Nov 9, 2016 | S | 111,349 | $8.3244 | D | 901,067 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common Stock | Nov 10, 2016 | M | 33,247 | $1.51 | A | 934,314 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common StockF2 | Nov 10, 2016 | S | 33,247 | $8.9015 | D | 901,067 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common Stock | Nov 11, 2016 | M | 14,216 | $1.51 | A | 915,283 | I | James N. Wilson and Pamela D. Wilson Trust |
| Common StockF3 | Nov 11, 2016 | S | 14,216 | $9.1015 | D | 901,067 | I | James N. Wilson and Pamela D. Wilson Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $1.51 | Nov 9, 2016 | M | 111,349 | D | — | May 18, 2017 | Common Stock | 111,349 | 47,463 | D |
| Stock Option (Right to Buy)F4 | $1.51 | Nov 10, 2016 | M | 33,247 | D | — | May 18, 2017 | Common Stock | 33,247 | 14,216 | D |
| Stock Option (Right to Buy)F4 | $1.51 | Nov 11, 2016 | M | 14,216 | D | — | May 18, 2017 | Common Stock | 14,216 | 0 | D |
Explanation of responses
- F1Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.27 to $8.375 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.
- F2Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.86 to $9.039 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.91 to $9.36 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.
- F4Fully Exercisable.